Uniform protein labeling in intact tissues is a challenge. An approach that allows antibodies to seep within organs could ...

Q4 2024 Earnings Call Transcript January 31, 2025 AbbVie Inc. misses on earnings expectations. Reported EPS is $2.16 EPS, ...

Detailed price information for Y-Mabs Therapeutics Inc (YMAB-Q) from The Globe and Mail including charting and trades.

Increased use of ventilation and air cleaners, designed to mitigate the spread of viral infections in hospitals, is likely to have unpredictable effects and may cause viral particles to move around ...

AbbVie’s ABBV 2024 revenue grew 4.6% on a constant currency basis, with 2025 guidance of 5.7% growth and new 2027 guidance for combined sales of immunology drug Skyrizi and Rinvoq of $31 billion (up ...

Judge ruled that more information is needed to determine whether the cull order by the Canadian Food Inspection Agency was ...

Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being recorded. If you have any objections, you may disconnect at this time. I would ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

A team of international researchers led by scientists at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, with its National Medical ...

Cigna To Reform Prior Authorization, Provider Services In 2025 The Cigna Group will spend up to $150 million to reform its prior authorization, patient advocacy and provider services this year, CEO ...